Mid-year results from a Belgian 2019 pilot project designed to encourage the uptake of anti-TNF biosimilars adalimumab and etanercept outside of the hospital setting show that prescribing rates are moving in the right direction but still need a substantial lift to achieve the full potential of biosimilars, according to local off-patent industry association Medaxes.
Acknowledging that the incentives offered by the project were provided due to the fact that “the use of biosimilars in...






